Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Range Nuclear Renaissance ETF (NUKZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Range Nuclear Renaissance ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Range Nuclear Renaissance ETF trades at $61.26 (market cap $698.21M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 18× Range Nuclear Renaissance ETF's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Range Nuclear Renaissance ETF for 18 Days on average.
| HALO | NUKZ | |
|---|---|---|
Market Cap | $12.58B | $698.21M |
Volume | 2,179,278 | 57,444 |
Sector | Health | Sector/Thematic |
52-Week High | $115.22 | $76.23 |
52-Week Low | $61.63 | $60.23 |
Typical Hold Time | 1 Days | 18 Days |
Enterprise Value | $14.49B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Range Nuclear Renaissance ETF
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →
